Statements

We position ourselves for customised and sensible solutions.

Statement relating to the Report from the CMDh meeting, 24-26 March 2020

Discussion to date: April 2020

COVID-19 outbreak and user testing of package leaflets

Statement relating to the ePI intended for use in the European Union

Discussion to date: January 2019

Statement relating to the Excipients Guideline draft on sodium

Discussion to date: May 2015

Excipients Guideline draft on sodium - May 2015 (PDF)

Statement relating to the Excipients Guideline draft on sodium laurilsulfate

Discussion to date: September 2015

Excipients Guideline draft on sodium laurilsulfate - September 2015 (PDF)

Statement relating to the QRD template draft

Discussion to date: April 2012

QRD template draft - April 2012 (PDF)

Statement relating to the QRD template draft

Discussion to date: July 2012

QRD template draft - July 2012 (PDF)

1st statement relating to the QRD template draft

Discussion to date: February 2010

QRD template - draft February 2010 (PDF)

2nd statement relating to the QRD template draft

Discussion to date: October 2010


QRD template - draft February 2010 (PDF)

Proposals to optimise the German QRD template

German QRD Template: Discussion and proposals to date - June 2007

Statement relating to the draft: 2nd proclamation of the revised version regarding the recommendations for package insert design according to paragraph 11 of the German drug law for human pharmaceuticals

Discussion to date: April 2006

Statement relating to the Readability Guideline draft 2006

Discussion to date: September 2006

Guideline on the readability of the label and package leaflet of medicinal products for human use - Draft (PDF)

Statement relating to the IQWIG health information draft

Discussion to date: October 2006


Last update: 18.04.2024

  Contact
  +49 3641 549396